GU Cancers 2024 | Ipilimumab plus nivolumab with sacituzumab govitecan in mUC

Rohit Jain, MD, MPH, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, discusses the trial design of an ongoing Phase I/II trial (NCT04863885) of sacituzumab govitecan, a Trop-2 directed antibody-drug conjugate, with ipilimumab and nivolumab as first-line therapy for cisplatin-ineligible metastatic urothelial carcinoma (mUC). The Phase I portion determined the recommended dose and the study progressed to Phase II. The primary endpoint is the objective response rate (ORR) and exploratory biomarker analyses will be conducted using tumor and blood samples. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.